Editas Medicine Inc. (EDIT) Sees Unusually-High Trading Volume
Editas Medicine Inc. (NASDAQ:EDIT) shares saw an uptick in trading volume on Monday . 301,908 shares changed hands during mid-day trading, a decline of 3% from the previous session’s volume of 312,049 shares.The stock last traded at $17.49 and had previously closed at $18.33.
Several research firms have commented on EDIT. Jefferies Group began coverage on shares of Editas Medicine in a research note on Thursday, June 2nd. They issued a “hold” rating and a $35.00 price target for the company. Zacks Investment Research upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a research note on Wednesday, June 1st. Finally, Cowen and Company restated a “buy” rating on shares of Editas Medicine in a research note on Monday, May 16th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $33.50.
The stock has a 50 day moving average of $23.08 and a 200-day moving average of $29.39. The stock’s market capitalization is $616.74 million.
Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.54). Equities analysts anticipate that Editas Medicine Inc. will post ($2.59) earnings per share for the current year.
Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.